Thu, Nov 27, 2014, 11:30 AM EST - U.S. Markets closed for Thanksgiving Day

Recent

% | $
Quotes you view appear here for quick access.

Boston Scientific Corporation Message Board

  • bsxisgood bsxisgood Jun 8, 2012 10:07 PM Flag

    JNJ can write a check for BSX!!!

    JNJ has over 30 billion dollars in cash on it's balance sheet as of 3/31/12.

    JNJ could easily write a 15 billion dollar check to purchase BSX! That would value BSX at over $10!!! I think BSX should hold out for $12/share!!!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • -JNJ exited the stent market because JNJ had an inferior stent and couldn't compete with BSX.

      -JNJ exited the stent market in order to clear anti-trust hurdles if they were to now buy BSX.

      -JNJ sent their top medical device executive (Mahoney) to sniff around at BSX and become BSX's CEO in November.

      -BSX has reduced it's longterm debt from 6 billion in 2009 to 4 billion in 2012 to become more attractive to a potential suitor like JNJ.

      -BSX has initiated a stock buyback plan in order to reduce the float and make an acquisition more attractive to a potential suitor like JNJ.

      Even if JNJ was to split up it's medical device unit into a standalone separate company, they would still buy BSX. Abbott is also separating out it's medical device division into a separate company. BSX could be bought by both JNJ and Abbott, with JNJ getting the stents, and Abbott getting the defib business. Just remember that JNJ wanted Guidant. Now they can get it at a much much lower price.

      Short interest has gone from 48,789,645 in June of last year, to 23,082,590 on 5/31/12! Shorts are covering because they see Nicholas and Abele transferring shares into a protected trust.

      That is my read on BSX. Target buyout price $10-$12.

      • 1 Reply to bsxisgood
      • "Shorts are covering because they see Nicholas and Abele transferring shares into a protected trust."

        That makes NO sense at all. If shorts were covering, the price would be higher, NOT LOWER!

        What makes you think Nicholas and Abele are transferring shares into a protected trust, you gotta link?

        And while you're at it, what makes you think JNJ is interested in this poor performer? You gotta link for that too? I didn't think so.

        Where'd you get the "$10-$12' figure?

        Its hard to believe, because its spent most of this year BELOW $6!!!

        I guess the stock didn't get that memo...

    • -JNJ exited the stent market because JNJ had an inferior stent and couldn't compete with BSX.

      -JNJ exited the stent market in order to clear anti-trust hurdles if they were to now buy BSX.

      -JNJ sent their top medical device executive (Mahoney) to sniff around at BSX and become BSX's CEO in November.

      -BSX has reduced it's longterm debt from 6 billion in 2009 to 4 billion in 2012 to become more attractive to a potential suitor like JNJ.

      -BSX has initiated a stock buyback plan in order to reduce the float and make an acquisition more attractive to a potential suitor like JNJ.

      Even if JNJ was to split up it's medical device unit into a standalone separate company, they would still buy BSX. Abbott is also separating out it's medical device division into a separate company. BSX could be bought by both JNJ and Abbott, with JNJ getting the stents, and Abbott getting the defib business. Just remember that JNJ wanted Guidant. Now they can get it at a much much lower price.

      That is my read on BSX. Target buyout price $10-$12.

      ________________________________________________________________________________________________________________________________________

    • JNJ has over 30 billion dollars in cash on it's balance sheet as of 3/31/12.

      JNJ could easily write a 15 billion dollar check to purchase BSX! That would value BSX at over $10!!! I think BSX should hold out for $12/share!!!

      _________________________________________________________________________________________

    • Goldman Sachs has called for the breakup of JNJ. If anything, BSX might be able to purchase JNJ's medical device group, but even if it did, it wouldn't amount to much, if you consider cotton swabs and band-aids as medical devices. Other than that, JNJ doesn't have anything.

      • 1 Reply to gluteusmaximus80
      • gluteus,

        I respectfully disagree. JNJ needs BSX now more than ever.

        -JNJ exited the stent market because JNJ had an inferior stent and couldn't compete with BSX.

        -JNJ exited the stent market in order to clear anti-trust hurdles if they were to now buy BSX.

        -JNJ sent their top medical device executive (Mahoney) to sniff around at BSX and become BSX's CEO in November.

        -BSX has reduced it's longterm debt from 6 billion in 2009 to 4 billion in 2012 to become more attractive to a potential suitor like JNJ.

        -BSX has initiated a stock buyback plan in order to reduce the float and make an acquisition more attractive to a potential suitor like JNJ.

        Even if JNJ was to split up it's medical device unit into a standalone separate company, they would still buy BSX. Abbott is also separating out it's medical device division into a separate company. BSX could be bought by both JNJ and Abbott, with JNJ getting the stents, and Abbott getting the defib business. Just remember that JNJ wanted Guidant. Now they can get it at a much much lower price.

        That is my read on BSX. Target buyout price $10-$12.

 
BSX
12.81-0.05(-0.39%)Nov 26 4:01 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
SeaDrill Limited
NYSEWed, Nov 26, 2014 4:01 PM EST
AGCO Corporation
NYSEWed, Nov 26, 2014 4:05 PM EST